Literature DB >> 16985627

Advances in prostate cancer treatment: highlights from the 2nd international prostate cancer congress, st. Thomas, u.s. Virgin islands, july 17-20, 2002.

Matthew B Gretzer, Alan W Partin.   

Abstract

Entities:  

Year:  2003        PMID： 16985627      PMCID： PMC1473003     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  78 in total

1.  RESPONSE: re: tomatoes, tomato-based products, lycopene, and prostate cancer: review of the epidemiologic literature

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

2.  Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis.

Authors:  E T Goluboff; A Shabsigh; J A Saidi; I B Weinstein; N Mitra; D Heitjan; G A Piazza; R Pamukcu; R Buttyan; C A Olsson
Journal:  Urology       Date:  1999-02       Impact factor: 2.649

3.  Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence.

Authors:  Matthew B Gretzer; Jonathan I Epstein; Charles R Pound; Patrick C Walsh; Alan W Partin
Journal:  Urology       Date:  2002-12       Impact factor: 2.649

4.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

5.  111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.

Authors:  D Kahn; R D Williams; M J Manyak; M K Haseman; D W Seldin; J A Libertino; R T Maguire
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

6.  Follow-up evaluation of a phase II prostate cancer vaccine trial.

Authors:  B A Tjoa; S J Simmons; A Elgamal; M Rogers; H Ragde; G M Kenny; M J Troychak; A L Boynton; G P Murphy
Journal:  Prostate       Date:  1999-07-01       Impact factor: 4.104

Review 7.  Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature.

Authors:  E Giovannucci
Journal:  J Natl Cancer Inst       Date:  1999-02-17       Impact factor: 13.506

8.  Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

Authors:  W K Kelly; T Curley; S Slovin; G Heller; J McCaffrey; D Bajorin; A Ciolino; K Regan; M Schwartz; P Kantoff; D George; W Oh; M Smith; D Kaufman; E J Small; L Schwartz; S Larson; W Tong; H Scher
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

9.  SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial.

Authors:  E A Klein; I M Thompson; S M Lippman; P J Goodman; D Albanes; P R Taylor; C Coltman
Journal:  J Urol       Date:  2001-10       Impact factor: 7.450

10.  Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group.

Authors:  L C Clark; G F Combs; B W Turnbull; E H Slate; D K Chalker; J Chow; L S Davis; R A Glover; G F Graham; E G Gross; A Krongrad; J L Lesher; H K Park; B B Sanders; C L Smith; J R Taylor
Journal:  JAMA       Date:  1996-12-25       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.